The CXCL10/CXCR3 axis in acute respiratory distress syndrome

doi:10.16352/j.issn.1001-6325.2024.06.0892

Abstract

Abstract: The CXC chemokine ligand-10/CXC receptor-3 (CXCL10/CXCR3) axis, a crucial pathway mediating Th1-type immunity, substantially contributes to the development of acute respiratory distress syndrome(ARDS) by enhancing inflammatory storms. It additionally promotes vascular endothelial apoptosis and impedes vasculature repair, elevating the risk of pulmonary vascular thrombosis. Conversely, this axis plays a protective role in limiting extra-cellular matrix deposition and modulating cell migration, thereby mitigating pulmonary fibrosis. The various mechanisms of the CXCL10/CXCR3 axis in the pathogenesis and progression of ARDS could offer novel insights for the diagnosis and treatment of ARDS.

Key words: CXCL10/CXCR3 axis, acute respiratory distress syndrome, inflammations, pulmonary embolism, pulmonary fibrosis

CLC Number:

R563.8

SHENG Qi, TONG Jin. The CXCL10/CXCR3 axis in acute respiratory distress syndrome[J]. Basic & Clinical Medicine, 2024, 44(6): 892-896.

References 24

[1]	Liu Y, Xiang D, Zhang H, et al. Hypoxia-inducible factor-1: a potential target to treat acute lung injury[J]. Oxid Med Cell Longev,2020,2020:8871476. doi: 10.1155/2020/8871476.
[2]	Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know so far[J]. Front Immunol,2020,11:1446. doi:10.3389/fimmu.2020.01446.
[3]	Whyte CS, Morrow GB, Mitchell JL, et al. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19[J]. J Thromb Haemost, 2020, 18:1548-1555.
[4]	Ntatsoulis K, Karampitsakos T, Tsitoura E, et al. Commonalities between ARDS, pulmonary fibrosis and COVID-19: the potential of autotaxin as a therapeutic target[J]. Front Immunol, 2021, 12:687397. doi:10.3389/fimmu.2021.687397.
[5]	Caldarale F, Giacomelli M, Garrafa E, et al. Plasmacy-toid dendritic cells depletion and elevation of IFN-γ dependent chemokines CXCL9 and CXCL10 in children with multisystem inflammatory syndrome[J]. Front Immunol,2021, 12:654587. doi:10.3389/fimmu.2021.654587.
[6]	Callahan V, Hawks S, Crawford MA, et al. The pro-inflammatory chemokines CXCL9, CXCL10 and CXCL11 are upregulated following SARS-CoV-2 infection in an AKT-dependent manner[J]. Viruses, 2021, 13:1062. doi:10.3390/v13061062.
[7]	Wang W, Tan J, Xing Y, et al. p43 induces IP-10 expression through the JAK-STAT signaling pathway in HMEC-1 cells[J]. Int J Mol Med,2016,38:1217-1224.
[8]	Ichikawa A, Kuba K, Morita M, et al. CXCL10-CXCR3 enhances the development of neutrophil-mediated fulmin-ant lung injury of viral and nonviral origin[J]. Am J Respir Crit Care Med, 2013, 187:65-77.
[9]	Wells A. Moreno B, Hueso L, et al. Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity[J]. Microvasc Res,2022,139:104254. doi:10.1016/j.mvr.2021.104254.
[10]	Boyé K, Billottet C, Pujol N,et al. Ligand activation induces different conformational changes in CXCR3 receptor isoforms as evidenced by plasmon waveguide resonance (PWR)[J]. Sci Rep, 2017, 7:10703. doi:10.1038/s41598-017-11151-x.
[11]	Pandey V, Fleming-Martinez A, Bastea L, et al. CXCL10/CXCR3 signaling contributes to an inflammatory microenvironment and its blockade enhances progression of murine pancreatic precancerous lesions[J]. Elife, 2021, 10: e60646. doi:10.7554/eLife.60646.
[12]	Zhang J, Liu Y, Chen H, et al. MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization[J]. Cell Death Dis, 2022, 13:411. doi:10.1038/s41419-022-04802-z.
[13]	Chang YS, Ko BH, Ju JC, et al. SARS unique domain (SUD) of severe acute respiratory syndrome coronavirus induces NLRP3 inflammasome-dependent CXCL10-mediated pulmonary inflammation[J]. Int J Mol Sci, 2020, 21:3179. doi:10.3390/ijms21093179.
[14]	Lupieri A, Smirnova NF, Solinhac R, et al. Smooth muscle cells-derived CXCL10 prevents endothelial healing through PI3Kγ-dependent T cells response[J]. Cardiovasc Res, 2020, 116:438-449.
[15]	Petrai I, Rombouts K, Lasagni L,et al. Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B[J]. Int J Biochem Cell Biol, 2008, 40:1764-1774.
[16]	Feldman ED, Weinreich DM, Carroll NM, et al. Interferon gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells[J]. Ann Surg Oncol, 2006, 13:125-133.
[17]	Mariscal A, Zamora C, Díaz-Torné C, et al. Increase of circulating monocyte-platelet conjugates in rheumatoid arthritis responders to IL-6 blockage[J]. Int J Mol Sci, 2022, 23:5748. doi:10.3390/ijms23105748.
[18]	Lou J, Hu Y, Wu MD, et al. Endothelial cell-specific anticoagulation reduces inflammation in a mouse model of acute lung injury[J]. Acta Pharmacol Sin, 2019, 40:769-780.
[19]	Ghonim MA, Boyd DF, Flerlage T, et al. Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside[J]. J Clin Invest, 2023, 133:e170499. doi:10.1172/JCI170499.
[20]	Li LF, Yu CC, Huang CY, et al. Attenuation of ventilation-enhanced epithelial-mesenchymal transition through the phosphoinositide 3-Kinase-γ in a murine bleomycin-induced acute lung injury model[J]. Int J Mol Sci, 2023, 24:5538. doi:10.3390/ijms24065538.
[21]	Jandl K, Marsh LM, Mutgan AC,et al. Impairment of the NKT-STAT1-CXCL9 axis contributes to vessel fibrosis in pulmonary hypertension caused by lung fibrosis[J]. Am J Respir Crit Care Med, 2022, 206:981-998.
[22]	Groover MK, Richmond JM. Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases[J]. F1000Res, 2020, 9:1197. doi:10.12688/f1000research.26728.1.
[23]	Dillemans L, De Somer L, Neerinckx B, et al. A review of the pleiotropic actions of the IFN-inducible CXC chemokine receptor 3 ligands in the synovial microenvironment[J]. Cell Mol Life Sci, 2023, 80:78. doi:10.1007/s00018-023-04715-w.
[24]	Cui H, Zhang Q. Dexmedetomidine ameliorates lipopolysaccharide-induced acute lung injury by inhibiting the PI3K/Akt/FoxO1 signaling pathway[J]. J Anesth, 2021, 35:394-404.